What Causes Hodgkin's Lymphoma - More Evidence

The various white blood cells, as well as the red blood cells and the blood platelets, develop from blood stem cells in the bone marrow, orchestrated by different molecular switches called transcription factors. They tell the cells which direction "to go". Until now, it has been assumed that once human blood cells have developed into one direction they are no longer able to leave their path. However, experiments in mice have shown that mature B lymphocyte cells have the ability to do exactly this: reprogramming and developing into different cell lineages. Until now, it was unclear whether human blood cells can undergo similar processes.




Now, Drs. Mathas and Janz at the Max Delbruck Center for Molecular Medicine (MDC) Berlin-Buch (Germany) and the Charite University Medicine Berlin (Campus Virchow and Campus Buch), publishing in Nature Immunology (doi:10.1038/ni1285, 2005), were able to show that in Hodgkin Reed Sternberg cells, which originate from B cells, the program which steers the differentiation of B cells is defective. One of the central regulators of B cell development, called E2A, is blocked by two antagonists, known as Id2 and ABF-1. Following inhibition of E2A, B cell characteristics are lost and genes for markers of other immune cells, such as macrophages and T cells, which are not characteristic for B cells, are upregulated. Thus, the B cells have changed their appearance. These findings shed light on the extraordinary appearance of Hodgkin Reed Sternberg lymphoma cells.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap